Hong Kong Stock Market Update | Hengrui Pharma Surges Nearly 4% on First A-Share Buyback as Analysts Eye Growth in Non-Oncology Portfolio

Stock News09-18 10:20

HENGRUI PHARMA (01276) climbed nearly 4% in Hong Kong trading, with shares last up 3.2% at HK$45.80, on turnover of HK$59.53 million.

The move follows the company's announcement that it spent RMB 14.50 million on September 17, 2026, to repurchase 335,000 A-shares—marking its first such buyback. According to a research report from Zheshang Securities, the company's innovative drug sales revenue reached RMB 8.809 billion in the first half of 2026, up 16.38% year-on-year and accounting for 63.16% of total pharmaceutical sales revenue.

Notably, revenue from non-oncology innovative products hit RMB 2.545 billion during the period, representing a robust 73.97% year-on-year gain and contributing approximately 87% of the overall growth in innovative drug sales. The surge was primarily driven by Henggliflozin, along with newly National Reimbursement Drug List (NRDL)-included drugs such as Ivarmacitinib, Vunakizumab, and Recaticimab. The brokerage believes that as these newly listed products continue to ramp up, the non-oncology segment is well-positioned to sustain its contribution to product revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment